Healthcare provider profile · identity verified

Lori Eileen Johnson, CRNP

Nurse Practitioner · YORK, PA · NPI 1679159834

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	184	68
Lisinopril	Lisinopril	181	64
Amlodipine Besylate	Amlodipine Besylate	173	65
Levothyroxine Sodium	Levothyroxine Sodium	145	49
Methylprednisolone	Methylprednisolone	114	93
Azithromycin	Azithromycin	113	96
Metformin Hcl	Metformin Hcl	107	34
Pantoprazole Sodium	Pantoprazole Sodium	104	34
Omeprazole	Omeprazole	95	41
Albuterol Sulfate Hfa	Albuterol Sulfate	92	41
Hydrochlorothiazide	Hydrochlorothiazide	85	30
Losartan Potassium	Losartan Potassium	77	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	74	26
Duloxetine Hcl	Duloxetine Hcl	71	29
Metoprolol Succinate	Metoprolol Succinate	70	27
Metoprolol Tartrate	Metoprolol Tartrate	70	22
Furosemide	Furosemide	69	25
Rosuvastatin Calcium	Rosuvastatin Calcium	67	19
Gabapentin	Gabapentin	66	22
Simvastatin	Simvastatin	63	23
Clopidogrel	Clopidogrel Bisulfate	58	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	54	47
Sertraline Hcl	Sertraline Hcl	49	18
Zolpidem Tartrate	Zolpidem Tartrate	49	14
Fluticasone Propionate	Fluticasone Propionate	48	16
Tamsulosin Hcl	Tamsulosin Hcl	45	13
Mupirocin	Mupirocin	41	33
Eliquis	Apixaban	39	14
Escitalopram Oxalate	Escitalopram Oxalate	39	14
Lorazepam	Lorazepam	39	15
Pravastatin Sodium	Pravastatin Sodium	38	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	36	29
Alprazolam	Alprazolam	35	13
Buspirone Hcl	Buspirone Hcl	35	16
Meloxicam	Meloxicam	35	15
Allopurinol	Allopurinol	31	12
Lovastatin	Lovastatin	31	14
Glipizide	Glipizide	30	14
Fluconazole	Fluconazole	29	16
Triamcinolone Acetonide	Triamcinolone Acetonide	29	20
Prednisone	Prednisone	28	16
Trazodone Hcl	Trazodone Hcl	27	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	26	25
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Tizanidine Hcl	Tizanidine Hcl	26	19
Atenolol	Atenolol	25	suppressed
Meclizine Hcl	Meclizine Hcl	25	11
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	16
Diazepam	Diazepam	19	suppressed
Famotidine	Famotidine	19	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Baclofen	Baclofen	17	12
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Ondansetron Odt	Ondansetron	15	12
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Arnuity Ellipta	Fluticasone Furoate	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Temazepam	Temazepam	14	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Oxycodone Hcl	Oxycodone Hcl	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Carisoprodol	Carisoprodol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error